AION Labs is a venture studio dedicated to building and investing in startups that leverage AI to revolutionize drug discovery and development. It is a unique partnership formed by AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and AWS, supported by the Israeli Innovation Authority.
By combining global pharmaceutical expertise with cutting-edge AI, AION Labs' unique venture studio model creates an optimal environment for startups by fostering cross-industry partnerships, funding opportunities, and offering unparalleled access to pharma R&D expertise and data.
In just three years, AION Labs has launched nine companies and built a proven venture-formation engine. The portfolio has executed multiple pilots with its founding pharma partners, as well as additional collaborations with other pharma and biotech organizations, generating meaningful scientific progress across the drug R&D value chain. The model has also attracted strong market validation, including multiple up-rounds, significant follow-on investment from leading global venture funds.
